MSH6 and prostate cancer: Even though we only identify one organotropic variant, the MSH6 mutation in lung metastasis of prostate cancer (FDR = 0.07, Supplementary Data 3), we observed from the survival analysis (Fig. 4c) that the patients with primary prostate cancer, the bone metastasis, and the liver metastasis suffer a dramatic decrease of the mean survival time as 33, 24, and 13 months, respectively, given a 40-month follow-up (Figs. 4c and 6a).